Exact Mass: 347.158009
Exact Mass Matches: 347.158009
Found 500 metabolites which its exact mass value is equals to given mass value 347.158009,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
EVOXINE
C18H21NO6 (347.13688060000004)
4,4-Disubstituted cyclohexenone
Methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
C22H21NO3 (347.15213560000007)
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
AS 1842856
C18H22FN3O3 (347.16451140000004)
Desmethylofloxacin
C17H18FN3O4 (347.12812800000006)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
5-Amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
C16H21N5O4 (347.15934660000005)
3-(4-((3-Phenoxybenzyl)amino)phenyl)propanoic acid
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
Nafamostat
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D051056 - Complement Inactivating Agents COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D006401 - Hematologic Agents > D000925 - Anticoagulants C471 - Enzyme Inhibitor > C783 - Protease Inhibitor D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Naproxcinod
C18H21NO6 (347.13688060000004)
Methyl 3-benzoyloxy-8-(3-hydroxypropyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
10,20-Dehydro[12,13-dehydroprolyl]-2-(1,1-dimethylallyltryptophyl)diketopiperazine
GW9508
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
(+)-6-(6-Hydroxy-1-methyl-2,3,5,6,7,7a-hexahydro-1H-indol-7-yl)-2,3,4-trimethoxy-benzaldehyd|(+)-6-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydro-1H-indol-7-yl)-2,3,4-trimethoxy-benzaldehyde
(+)-4-(6-methoxy-9-methyl-8-oxo-8,9-dihydro-[1,3]dioxolo[4,5-h]quinolin-7-yl)-2-methyl-butyric acid methyl ester|Pteleolin|Pteleoline
C18H21NO6 (347.13688060000004)
delta-(L-alpha-aminoadipoyl)-L-serine-D-valine|delta-(L-alpha-aminoadipyl)-L-seryl-D-valine|L,L,D-alpha-aminodipoyl-serinyl-valine
(2S)-1-[(6,7-dimethoxyfuro[2,3-b]quinolin-4-yl)oxy]-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
4,6,8-trimethoxy-3-(2-methoxy-3-methyl-but-3-enyl)-1-methyl-1H-quinolin-2-one|Ptelefolin-methylether|Ptelefolinmethylether
4-methoxy-3-methyl-5-[(2Z,11aS)-3at,11t-epoxy-1c-methyl-(11ar,11bc)-dodecahydro-furo[3,2-c]pyrido[1,2-a]azepin-2-ylidene]-5H-furan-2-one|pyridostemin|stemocurtisine
Foliosidine acetonide
Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Quinoline alkaloids, Foliosidine alkaloids
Ala Gly Asn Ser
Ala Gly Ser Asn
Ala Asn Gly Ser
Ala Asn Ser Gly
Ala Ser Gly Asn
Ala Ser Asn Gly
Gly Ala Asn Ser
Gly Ala Ser Asn
Gly Gly Lys Ser
Gly Gly Asn Thr
Gly Gly Gln Ser
Gly Gly Ser Lys
Gly Gly Ser Gln
Gly Gly Thr Asn
Gly Lys Gly Ser
Gly Lys Ser Gly
Gly Asn Ala Ser
Gly Asn Gly Thr
Gly Asn Ser Ala
Gly Asn Thr Gly
Gly Gln Gly Ser
Gly Gln Ser Gly
Gly Ser Ala Asn
Gly Ser Gly Lys
Gly Ser Gly Gln
Gly Ser Lys Gly
Gly Ser Asn Ala
Gly Ser Gln Gly
Gly Thr Gly Asn
Gly Thr Asn Gly
Lys Gly Gly Ser
Lys Gly Ser Gly
Lys Ser Gly Gly
Asn Ala Gly Ser
Asn Ala Ser Gly
Asn Gly Ala Ser
Asn Gly Gly Thr
Asn Gly Ser Ala
Asn Gly Thr Gly
Asn Ser Ala Gly
Asn Ser Gly Ala
Asn Thr Gly Gly
Gln Gly Gly Ser
Gln Gly Ser Gly
Gln Ser Gly Gly
Ser Ala Gly Asn
Ser Ala Asn Gly
Ser Gly Ala Asn
Ser Gly Gly Lys
Ser Gly Gly Gln
Ser Gly Lys Gly
Ser Gly Asn Ala
Ser Gly Gln Gly
Ser Lys Gly Gly
Ser Asn Ala Gly
Ser Asn Gly Ala
Ser Gln Gly Gly
Thr Gly Gly Asn
Thr Gly Asn Gly
Thr Asn Gly Gly
GW 9508
C22H21NO3 (347.15213560000007)
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
1-naphthyl-n-acetyl-beta-d-glucosaminide
C18H21NO6 (347.13688060000004)
[5-(4-Methylphenyl)-1,2-oxazol-4-yl](4-phenyl-1-piperazinyl)metha none
Methyl 4-((5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl)methyl)piperidine-1-carboxylate
Boc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N-phenyl- (9CI)
(E)-Methyl 3-(2-((tert-butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)acrylate
Boc-(R)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Adiphenine Hydrochloride
C20H26ClNO2 (347.16519660000006)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects[1][2][3].
2H-Pyrrol-2-one, 4-acetyl-1-(3-chloro-4-methylphenyl)-5-cyclohexyl-1,5-dihydro-3-hydroxy-
C19H22ClNO3 (347.1288132000001)
6-Chloro-2,3,4,5-tetrahydro-7,8-dimethoxy-1-(4-methoxyphenyl)-1H-3-benzazepine
C19H22ClNO3 (347.1288132000001)
Boc-(R)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
Boc-(S)-3-Amino-4-(3-trifluoromethyl-phenyl)-butyric acid
C16H20F3NO4 (347.1344356000001)
2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-TOSYL-1H-PYRROLE
C17H22BNO4S (347.13625220000006)
Methanone, [4-(5-chloro-2-methylphenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)
C18H22ClN3O2 (347.14004620000003)
Methanone, [4-(3-chlorophenyl)-1-piperazinyl][3-methyl-5-(1-methylethyl)-4-isoxazolyl]
C18H22ClN3O2 (347.14004620000003)
6-AMINO-1-[3-(CYCLOPENTYLOXY)-4-METHOXYBENZYL]-2-THIOXO-2,3-DIHYDROPYRIMIDIN-4(1H)-ONE
C17H21N3O3S (347.13035560000003)
(R)-(+)-N,N-DIMETHYL-1-(1-NAPHTHYL)ETHYLAMINE
C22H21NO3 (347.15213560000007)
1-benzyl-4-(2-methoxy-phenyl)-pyrrolidine-3-carboxylic acid hydrochloride
C19H22ClNO3 (347.1288132000001)
trans-1-Benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
C19H22ClNO3 (347.1288132000001)
ethyl 2-piperazine-4-(4-methoxy)phenyl thiazole-5-carboxylate
C17H21N3O3S (347.13035560000003)
1-(tert-butoxycarbonyl)spiro[chroMan-4,4-piperidine]-2-carboxylic acid
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride
C20H26ClNO2 (347.16519660000006)
(3R)-3-Piperidinecarboxylic acid, 3-(phenylmethyl)-, 1,2,2-trimethylhydrazide, hydrochloride (1:2)
N-[(2S)-3-Amino-2-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]acetamide hydrochloride (1:1)
C15H23ClFN3O3 (347.14118900000005)
DIETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(4-F&
C19H22FNO4 (347.15327840000003)
3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-TOSYL-1H-PYRROLE
C17H22BNO4S (347.13625220000006)
nalorphine hydrochloride ciii (250 mg)
C19H22ClNO3 (347.1288132000001)
6-nitro-2-[(4-phenylpiperidin-1-yl)methyl]quinoline
1-TERT-BUTYL 3-METHYL 3-BENZYL-4-OXOPIPERIDINE-1,3-DICARBOXYLATE
naproxcinod
C18H21NO6 (347.13688060000004)
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D002317 - Cardiovascular Agents > D020030 - Nitric Oxide Donors C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine
4-Methoxy-1-methyl-8-[(2,2,5,5-tetramethyl-1,3-dioxolan-4-yl)methoxy]quinolin-2-one
N2-(2-methoxyphenyl)-6-(3-methyl-2-benzofuranyl)-1,3,5-triazine-2,4-diamine
N-cyclopropyl-2,6-dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
2-(Cyclohexylmethylamino)-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile
N-(Cyclopropylmethyl)-2-Methyl-5-(5-Methyl-1,3,4-Oxadiazol-2-Yl)biphenyl-4-Carboxamide
(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
C18H21NO6 (347.13688060000004)
Nafamostat
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D051056 - Complement Inactivating Agents COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D006401 - Hematologic Agents > D000925 - Anticoagulants C471 - Enzyme Inhibitor > C783 - Protease Inhibitor D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
BSPBio_000729
C18H21NO6 (347.13688060000004)
(1E,2Z)-3-hydroxy-5,9,17-trioxo-4,5:9,10-disecoandrosta-1(10),2-dien-4-oate
(1R,2R,5R,8R,9S,10R,11R,12R,13S)-12,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11R,12S)-5,12-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11S,13R)-5,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(4R)-4,5-dihydroxy-4,6-bis(3-methylbut-2-enyl)-2-(2-methylpropanoyl)-3-oxocyclohexa-1,5-dien-1-olate
C20H27O5- (347.18583920000003)
(1R,2S,3S,4R,6S,8R,9R,12R)-4-formyl-6-hydroxy-8-(hydroxymethyl)-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2-carboxylate
C20H27O5- (347.18583920000003)
(3E)-3-(1-hydroxy-2,4-dimethylhexylidene)-5-[hydroxy-(4-hydroxyphenyl)methyl]pyrrolidine-2,4-dione
Leu-Thr-Asp
A tripeptide composed of L-leucine, L-threonine and L-aspartic acid joined in sequence by peptide linkages.
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine
2-hydroxy-2,2-bis(4-methylphenyl)-N-(2-pyridinyl)acetohydrazide
1-[4-(3,5-Dimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide
C17H21N3O3S (347.13035560000003)
Glu-Ile-Ser
A tripeptide composed of L-glutamic acid, L-isoleucine and L-serine joined by peptide linkages.
N-[(3,5-dimethoxyphenyl)methyl]-1-(2,3,4-trimethoxyphenyl)methanamine
18-oxoresolvin E1(1-)
C20H27O5- (347.18583920000003)
An icosanoid anion resulting from the removal of a proton from the carboxy group of 18-oxoresolvin E1; major species at pH 7.3.
1-(3-Methoxyphenyl)-3-[5-(2-methyl-1-piperidinyl)-1,3,4-thiadiazol-2-yl]urea
C16H21N5O2S (347.14158860000003)
2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-N-(3-methoxyphenyl)acetamide
1-[2-(Dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(thiophen-2-ylmethyl)thiourea
5-[[3-Methyl-1-(4-methylphenyl)-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one
N-[(4-tert-butylcyclohexylidene)amino]-3-chloro-5-(trifluoromethyl)-2-pyridinamine
3-(1,3-Dihydrobenzimidazol-2-ylidene)-1-pentylquinoline-2,4-dione
7-(diethylamino)-4-(1-methyl-1H-benzimidazol-2-yl)-2H-chromen-2-one
5-dioxooctahydro-1H-inden-4-yl]-6-oxoocta-2,4-dienoate
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
(2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3-oxanyl]cyclopropanecarboxamide
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
(5S,6Z,8E,10E,14Z)-5-hydroxy-12,20-dioxoicosa-6,8,10,14-tetraenoate
C20H27O5- (347.18583920000003)
3-[(2,5-Dimethoxyphenyl)iminomethyl]-1,5-dioxaspiro[5.5]undecane-2,4-dione
C18H21NO6 (347.13688060000004)
Butyl N-trifluoroacetyl 2-N-methylaminoethyl phosphonate
Dibutyl 1-(N-trifuoroacetylamino)propylphosphonate
methyl {2-[(1R)-1-(3,4-dimethoxyphenyl)-4-oxocyclohex-2-en-1-yl]ethyl}methylcarbamate
Eliprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). IC50 value: Target: NR2B-NMDA antagonist Human N-type Ca2+ channel currents were inhibited by ifenprodil and eliprodil with IC50 values of 50 microM and 10 microM respectively whereas P-type Ca2+ channel currents were inhibited reversibly by ifenprodil and eliprodil with approximate IC50 values of 60 microM and 9 microM respectively. eliprodil (1 microm) produced a moderate reverse rate-dependent prolongation of the action potential duration (7.4+/-1.5, 8.9+/-2.1 and 9.9+/-1.8\% at cycle lengths of 300, 1000 and 5000 ms, respectively; n=9).
FPL64176
C22H21NO3 (347.15213560000007)
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
(2R)-1-[(4,8-dimethoxy-7-furo[2,3-b]quinolinyl)oxy]-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
1-naphthyl N-acetyl-beta-D-glucosaminide
C18H21NO6 (347.13688060000004)
An N-acetyl-beta-D-glucosaminide in which the anomeric hydroxy hydrogen is replaced by a 1-naphthyl group.
GP531
C16H21N5O4 (347.15934660000005)
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
3-(acetyloxy)-1-{8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene}butan-2-yl 2-methylpropanoate
(1s,13s,15r,16s,18r,19r)-9,15-dimethoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2,4(8),9-trien-19-ol
C18H21NO6 (347.13688060000004)
(2r)-1-({4,7-dimethoxyfuro[2,3-b]quinolin-6-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
6-(6-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
methyl 2-hydroxy-3-{4-[5-hydroxy-4-(2-methylpropyl)-2-oxopyrrol-3-yl]phenoxy}propanoate
C18H21NO6 (347.13688060000004)
(5s,9bs,11r,12s)-7,8,11-trimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-5,12-diol
(2z,5r,7r,8s,9r)-15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
n-[(3as,4s,5s,11as)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
n-{6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl}-2-methylpropanimidic acid
9,15-dimethoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2(10),3,8-trien-11-ol
C18H21NO6 (347.13688060000004)
n-[2,4-dihydroxy-5-(3-methoxy-3-oxopropyl)phenyl]-7-methylocta-2,4-dienimidic acid
(2s)-1-({7,8-dimethoxyfuro[2,3-b]quinolin-4-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
3-(acetyloxy)-1-[(10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl 2-methylpropanoate
3-methoxy-4-methyl-5-[(1s,9r,10r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
9,15-dimethoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2,4(8),9-trien-19-ol
C18H21NO6 (347.13688060000004)
15-hydroxy-9,16-dimethoxy-3-methyl-7,11-dioxa-3-azapentacyclo[8.8.0.0²,⁶.0⁶,⁸.0¹³,¹⁸]octadeca-13(18),14,16-trien-12-one
C18H21NO6 (347.13688060000004)
(1r,5's,6'r,7'ar)-5',6'-dihydroxy-5,6-dimethoxy-1'-methyl-3',5',6',7'a-tetrahydro-2'h-spiro[2-benzofuran-1,7'-indol]-3-one
C18H21NO6 (347.13688060000004)
6-(5-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
(2s,3s,6r,12r)-3,12-dihydroxy-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-10-ium-10-olate
C18H21NO6 (347.13688060000004)
1-({7,8-dimethoxyfuro[2,3-b]quinolin-4-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
4,6,8-trimethoxy-3-[(2s)-2-methoxy-3-methylbut-3-en-1-yl]-1-methylquinolin-2-one
4,5,6-trimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol
(2r,3s)-3-(acetyloxy)-1-[(1r,3s,10z)-8-methyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]deca-6,8-dien-10-ylidene]butan-2-yl 2-methylpropanoate
4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadeca-11(17),12-diene-3,8,15-trione
C18H21NO6 (347.13688060000004)
11-β-hydroxycephalotaxine β-n-oxide
C18H21NO6 (347.13688060000004)
{"Ingredient_id": "HBIN000367","Ingredient_name": "11-\u03b2-hydroxycephalotaxine \u03b2-n-oxide","Alias": "NA","Ingredient_formula": "C18H21NO6","Ingredient_Smile": "COC1=CC23CCC[N+]2(CC(C4=CC5=C(C=C4C3C1O)OCO5)O)[O-]","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9901","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
acanthamolide
{"Ingredient_id": "HBIN014338","Ingredient_name": "acanthamolide","Alias": "NA","Ingredient_formula": "C19H25NO5","Ingredient_Smile": "CC1=CC2C(C(C(C(=CCC1)C=O)NC(=O)C(C)C)O)C(=C)C(=O)O2","Ingredient_weight": "347.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "76","TCMSP_id": "NA","TCM_ID_id": "7248;21448","PubChem_id": "118855998","DrugBank_id": "NA"}
Aporphin
C19H22ClNO3 (347.1288132000001)
{"Ingredient_id": "HBIN016514","Ingredient_name": "Aporphin","Alias": "NA","Ingredient_formula": "C19H22ClNO3","Ingredient_Smile": "C[NH+]1CCC2=CC(=C(C3=C2C1CC4=C3C(=CC=C4)OC)O)OC.[Cl-]","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "32984","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
4,6-dihydroxy-12-methoxy-7-methyl-4-(sec-butyl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C17H21N3O5 (347.14811360000004)
(1s,8r,10r,17r)-4,5,6-trimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol
13,14-dimethyl-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-13-ium-19-carboxylate
6-[(1r,2s,4ar,5r,8ar)-5-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
(4e,6e)-7-{[1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
(1s,13r,15r,16s,18r,19r)-9,15-dimethoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2,4(8),9-trien-19-ol
C18H21NO6 (347.13688060000004)
n-[(3ar,4s,5s,11ar)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
(2r)-1-({4,6-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
(1r,9r,12s,13s)-4,11-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,10-tetraene-3,12,13-triol
4-methoxy-3-methyl-5-[(13e)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
6-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl)-2,3,4-trimethoxybenzaldehyde
(3z)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
6-[(6r,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-2,3,4-trimethoxybenzaldehyde
(2s)-1-({6,7-dimethoxyfuro[2,3-b]quinolin-4-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
(3s,4s)-4-(5,7-dihydroxy-2-methyl-4-oxochromen-8-yl)-1-methylpiperidin-3-yl acetate
C18H21NO6 (347.13688060000004)
(23r)-13-methoxy-5,7-dioxa-19-azahexacyclo[15.7.0.0²,¹⁰.0⁴,⁸.0¹¹,¹⁶.0¹⁹,²³]tetracosa-1(17),2(10),3,8,11(16),12,14-heptaene
C22H21NO3 (347.15213560000007)
(2s)-2-{[(2s,3r)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxybutylidene]amino}butanedioic acid
4,6,8-trimethoxy-3-(2-methoxy-3-methylbut-3-en-1-yl)-1-methylquinolin-2-one
(1s,4z,6s,7r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadeca-11(17),12-diene-3,8,15-trione
C18H21NO6 (347.13688060000004)
(1s,2s,6r,8s,9r,10s)-15-hydroxy-9,16-dimethoxy-3-methyl-7,11-dioxa-3-azapentacyclo[8.8.0.0²,⁶.0⁶,⁸.0¹³,¹⁸]octadeca-13(18),14,16-trien-12-one
C18H21NO6 (347.13688060000004)
4-methoxy-3-methyl-5-[(1r,9s,10r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
1-({6,7-dimethoxyfuro[2,3-b]quinolin-4-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
(1s,10s,12r,16r)-16-hydroxy-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate
4-{[(1r,2r,4as,5r,8ar)-2-ethyl-5-hydroxy-1,6-dimethyl-4-oxo-2,3,4a,5,8,8a-hexahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2h-pyrrol-3-one
(4r,7r)-4,6-dihydroxy-12-methoxy-7-methyl-4-(sec-butyl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C17H21N3O5 (347.14811360000004)
4-methoxy-3-methyl-5-[(1r,9r,11r,12s,13z)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
13-methoxy-5,7-dioxa-19-azahexacyclo[15.7.0.0²,¹⁰.0⁴,⁸.0¹¹,¹⁶.0¹⁹,²³]tetracosa-1(17),2(10),3,8,11(16),12,14-heptaene
C22H21NO3 (347.15213560000007)
(2s)-1-({4,8-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
methyl (1s,3s,11r,13r,14e)-3-methoxy-14-(2-methoxy-2-oxoethylidene)-9-azatetracyclo[7.5.0.0¹,⁶.0¹¹,¹³]tetradec-5-ene-13-carboxylate
(3r,6r)-6-(1h-indol-3-ylmethyl)-3-isopropyl-6-(methylsulfanyl)pyrazine-2,3,5-triol
C17H21N3O3S (347.13035560000003)
(1s,13s,16s,18r)-13,18-dimethoxy-15-methyl-5,7,12-trioxa-15-azapentacyclo[11.7.0.0¹,¹⁶.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9-triene
15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
(2s,3s,6r,10r,12r)-3,12-dihydroxy-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-10-ium-10-olate
C18H21NO6 (347.13688060000004)
(2r)-1-({4,8-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
(1r,13s,16s,17r)-13,17-dihydroxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-16-yl acetate
C18H21NO6 (347.13688060000004)
n-[(3as,4s,5s,11ar)-6-formyl-4-hydroxy-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-5-yl]-2-methylpropanimidic acid
(3r,6r)-3-(1h-indol-3-ylmethyl)-6-isopropyl-6-(methylsulfanyl)pyrazine-2,3,5-triol
C17H21N3O3S (347.13035560000003)
(1s,13z)-12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
13,18-dimethoxy-15-methyl-5,7,12-trioxa-15-azapentacyclo[11.7.0.0¹,¹⁶.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9-triene
7-{[1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
3-(1h-indol-3-ylmethyl)-6-isopropyl-6-(methylsulfanyl)pyrazine-2,3,5-triol
C17H21N3O3S (347.13035560000003)
methyl (1r,3s,11r,13r,14e)-3-methoxy-14-(2-methoxy-2-oxoethylidene)-9-azatetracyclo[7.5.0.0¹,⁶.0¹¹,¹³]tetradec-5-ene-13-carboxylate
7,8,11-trimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-5,12-diol
(4r,5r,7e,9s,11r)-3,5,14-trihydroxy-4-methyl-17-oxa-2-azatricyclo[7.6.2.0¹²,¹⁶]heptadeca-1(15),2,7,12(16),13-pentaen-11-yl acetate
C18H21NO6 (347.13688060000004)
(1s,10r,12r)-16-hydroxy-4,5-dimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate
4-benzyl-5-hydroxy-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}pyrrol-2-one
C22H21NO3 (347.15213560000007)
4-methoxy-3-methyl-5-{12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene}furan-2-one
(1r,5s)-6-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
6-[(6s,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-2,3,4-trimethoxybenzaldehyde
methyl 4-{6-methoxy-9-methyl-8-oxo-2h-[1,3]dioxolo[4,5-h]quinolin-7-yl}-2-methylbutanoate
C18H21NO6 (347.13688060000004)
5-(4-methoxy-2-methylnaphthalen-1-yl)-3-methyl-1,2-dihydroisoquinoline-6,8-diol
C22H21NO3 (347.15213560000007)
3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
1-({4,6-dimethoxyfuro[2,3-b]quinolin-7-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
(1s,9s,12s,13s)-4,11-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,10-tetraene-3,12,13-triol
(3s)-7-{[(2s)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-[3-(acetyloxy)phenyl]-3-hydroxypropanoate
(3s,4e,6e)-7-{[(2s)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
(2e,4e)-n-[2,4-dihydroxy-5-(3-methoxy-3-oxopropyl)phenyl]-7-methylocta-2,4-dienimidic acid
6-[(1r,2s,4ar,6r,8ar)-6-hydroxy-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-[(2-hydroxyethyl)amino]-2-oxopyran-3-carbaldehyde
(3s,6s)-3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
6-(1h-indol-3-ylmethyl)-3-isopropyl-6-(methylsulfanyl)pyrazine-2,3,5-triol
C17H21N3O3S (347.13035560000003)
(2s)-1-({4,7-dimethoxyfuro[2,3-b]quinolin-6-yl}oxy)-3-methylbutane-2,3-diol
C18H21NO6 (347.13688060000004)
12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
(1r,4z,6r,7r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadeca-11(17),12-diene-3,8,15-trione
C18H21NO6 (347.13688060000004)
4-methoxy-3-methyl-5-[(1r,9r,10r,11r,12s,13e)-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-ylidene]furan-2-one
(2z,5s,7r,8s,9r)-15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
methyl (2r)-4-{6-methoxy-9-methyl-8-oxo-2h-[1,3]dioxolo[4,5-h]quinolin-7-yl}-2-methylbutanoate
C18H21NO6 (347.13688060000004)
(3r,4e,6e)-7-{[(2s)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-c-hydroxycarbonimidoyl}-3,5-dimethylhepta-4,6-dienoic acid
(5r,7r,8s,9r)-15,16-dimethoxy-10-methyl-18-oxa-10-azatetracyclo[7.7.1.1²,⁸.0¹³,¹⁷]octadeca-1(16),2,13(17),14-tetraene-5,7-diol
(1s,11r,13r,15r,16s,18r)-9,15-dimethoxy-5,7,17-trioxa-12-azahexacyclo[10.6.2.0¹,¹³.0²,¹⁰.0⁴,⁸.0¹⁶,¹⁸]icosa-2(10),3,8-trien-11-ol
C18H21NO6 (347.13688060000004)